CN113330020B - 用于治疗神经变性疾病的2-氟代的胆汁酸 - Google Patents

用于治疗神经变性疾病的2-氟代的胆汁酸 Download PDF

Info

Publication number
CN113330020B
CN113330020B CN201980085276.5A CN201980085276A CN113330020B CN 113330020 B CN113330020 B CN 113330020B CN 201980085276 A CN201980085276 A CN 201980085276A CN 113330020 B CN113330020 B CN 113330020B
Authority
CN
China
Prior art keywords
compound
dihydroxy
difluoro
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980085276.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113330020A (zh
Inventor
A·C·韦茅斯-威尔逊
B·J·P·林克劳
G·帕克尔
J·瓦茨
H·莫蒂博伊斯
O·班德曼
C·黑斯廷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Nzp Uk Ltd
Original Assignee
University of Southampton
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton, Nzp Uk Ltd filed Critical University of Southampton
Publication of CN113330020A publication Critical patent/CN113330020A/zh
Application granted granted Critical
Publication of CN113330020B publication Critical patent/CN113330020B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980085276.5A 2018-12-20 2019-12-20 用于治疗神经变性疾病的2-氟代的胆汁酸 Active CN113330020B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1820887.6 2018-12-20
GBGB1820887.6A GB201820887D0 (en) 2018-12-20 2018-12-20 Compounds
PCT/GB2019/053665 WO2020128514A1 (en) 2018-12-20 2019-12-20 2-fluorinated bile acids for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CN113330020A CN113330020A (zh) 2021-08-31
CN113330020B true CN113330020B (zh) 2024-04-05

Family

ID=65364420

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980085276.5A Active CN113330020B (zh) 2018-12-20 2019-12-20 用于治疗神经变性疾病的2-氟代的胆汁酸

Country Status (15)

Country Link
US (1) US20220073557A1 (cg-RX-API-DMAC7.html)
EP (1) EP3898645B1 (cg-RX-API-DMAC7.html)
JP (1) JP7503063B2 (cg-RX-API-DMAC7.html)
KR (1) KR102856276B1 (cg-RX-API-DMAC7.html)
CN (1) CN113330020B (cg-RX-API-DMAC7.html)
AU (1) AU2019411556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123333A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191521A1 (cg-RX-API-DMAC7.html)
ES (1) ES3036094T3 (cg-RX-API-DMAC7.html)
GB (1) GB201820887D0 (cg-RX-API-DMAC7.html)
IL (1) IL284093B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007551A (cg-RX-API-DMAC7.html)
SG (1) SG11202105465WA (cg-RX-API-DMAC7.html)
WO (1) WO2020128514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4486318A4 (en) * 2022-03-02 2026-02-25 Boyce Thompson Institute For Plant Res Inc Cysteamides, related therapeutic compositions and associated processes
GB202208151D0 (en) 2022-06-01 2022-07-13 Nzp Uk Ltd Compounds
GB202314563D0 (en) 2023-09-22 2023-11-08 Nzp Uk Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036379A2 (en) * 2012-08-31 2014-03-06 Metselex Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases
CN107531741A (zh) * 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
FR2934596B1 (fr) * 2008-07-30 2015-04-10 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
ITMI20121344A1 (it) * 2012-07-31 2014-02-01 Erregierre Spa Processo di preparazione di acido ursodesossicolico ad elevata purezza
CN103333216A (zh) * 2013-06-04 2013-10-02 苏州大学 5α-6-酮-胆甾烷类似物及其应用
US20150112089A1 (en) 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids
GB201812382D0 (en) * 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036379A2 (en) * 2012-08-31 2014-03-06 Metselex Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases
CN107531741A (zh) * 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸

Also Published As

Publication number Publication date
WO2020128514A1 (en) 2020-06-25
EP3898645C0 (en) 2025-06-25
CA3123333A1 (en) 2020-06-25
MX2021007551A (es) 2021-10-13
JP7503063B2 (ja) 2024-06-19
ES3036094T3 (en) 2025-09-12
GB201820887D0 (en) 2019-02-06
CN113330020A (zh) 2021-08-31
EP3898645A1 (en) 2021-10-27
AU2019411556A1 (en) 2021-06-10
IL284093B2 (en) 2025-07-01
IL284093B1 (en) 2025-03-01
JP2022514401A (ja) 2022-02-10
BR112021011189A2 (pt) 2021-08-31
KR102856276B1 (ko) 2025-09-05
AU2019411556B2 (en) 2025-04-03
EA202191521A1 (ru) 2021-09-10
US20220073557A1 (en) 2022-03-10
IL284093A (en) 2021-08-31
EP3898645B1 (en) 2025-06-25
KR20210125982A (ko) 2021-10-19
SG11202105465WA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
CN113735862B (zh) 一种治疗病毒感染的核苷类化合物及其用途
EP1728793B1 (en) 9-substituted 8-oxoadenine compound
CN118451059A (zh) 用于rna递送的可电离阳离子脂质
JP2003507327A (ja) 化学化合物
JP2022504697A (ja) Ssao阻害剤とその使用
KR102856276B1 (ko) 신경변성 질환의 치료를 위한 2-플루오린화된 담즙산
CN114805478A (zh) 氘代拟肽类化合物及其用途
KR20190134722A (ko) 치료 화합물 및 방법
CN121511234A (zh) 用于rna递送的可电离阳离子脂质
CN113272298A (zh) 用于治疗呼吸系统疾病的化合物和组合物
JP2008530074A (ja) Hm74a受容体アゴニストとしてのアントラニル酸誘導体
CN116514902A (zh) 氘代拟肽类化合物及其用途
JP2025518741A (ja) ミトコンドリア機能関連疾患治療用の3-アザステロイド化合物
JP2005527518A (ja) 新規なカルコン(chalcone)誘導体とその使用
CN112218878A (zh) Ntcp抑制剂
CN113620967B (zh) 一种α-倒捻子素衍生物及其制备方法和应用
CN104860847A (zh) 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物
HK40062202A (en) 2-fluorinated bile acids for the treatment of neurodegenerative diseases
HK40062202B (en) 2-fluorinated bile acids for the treatment of neurodegenerative diseases
EA046372B1 (ru) 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний
EP1425258A2 (en) Hydroxyeicosenoic acid analogs
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途
CN110938001A (zh) 绿原酸乙醇胺盐及用途
TW202130619A (zh) 硝羥喹啉前藥及其用途
HK1246718A1 (zh) 用於治疗囊性纤维化的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant